Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5516336 | 0.99 | ALDH1A1 (0.45) | ALDH1A1LMNAMAPTABCC4USP2 | |
| SCHEMBL3824079 | 0.85 | MAPT (0.41) | LMNAMAPTRECQLTSHR | |
| SCHEMBL4853542 | 0.84 | MAPT (0.40) | LMNAMAPTRECQLTSHR | |
| SCHEMBL4067200 | 0.82 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTABCC4USP2 | |
| SCHEMBL28522994 | 0.81 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTABCC4USP2 | |
| SCHEMBL3465910 | 0.80 | FAAH (0.52) | — | |
| SCHEMBL9344754 | 0.79 | FAAH (0.51) | — | |
| SCHEMBL27706232 | 0.75 | ALDH1A1 (0.40) | ALDH1A1LMNAMAPTABCC4USP2 | |
| SCHEMBL23200421 | 0.71 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTABCC4USP2 | |
| SCHEMBL1902663 | 0.71 | ALDH1A1 (0.70) | ALDH1A1LMNAMAPTABCC4USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030003070-A1 | Use of nanoscale active anti-dandruff ingredients | COGNIS DEUTSCHLAND GMBH & CO. KG (DE) | 2003-01-02 | — | — | US | claimed |
| EP-4376995-A1 | BIOBASED CORE-SHELL MICROCAPSULES | Symrise AG (DE) | 2024-06-05 | — | — | EP | disclosed |
| US-20240000746-A1 | New Cooling Agents and Preparations Containing Them | SYMRISE AG (DE) | 2024-01-04 | — | — | US | disclosed |
| EP-3432858-B1 | NON-THERAPEUTIC USE OF CARNOSINES | SYMRISE AG (DE) | 2023-12-27 | — | — | EP | disclosed |
| CN-113518613-B | Bio-based pearlescent wax | 巴斯夫欧洲公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230322878-A1 | COMPOUNDS FOR INDUCING TISSUE FORMATION AND USES THEREOF | HISTIDE AG (CH) | 2023-10-12 | — | — | US | disclosed |
| CN-116685575-A | Novel cooling substances and formulations containing these cooling substances | 西姆莱斯股份公司 | 2023-09-01 | — | — | CN | disclosed |
| US-11633407-B2 | Botanical extracts and compounds from Schinus plants and methods of use | EMORY UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230112887-A1 | Pentagalloyl Glucose Derived from Schinus Plants and Methods of Use | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-11578110-B2 | Compounds for inducing tissue formation and uses thereof | HISTIDE AG (CH) | 2023-02-14 | — | — | US | disclosed |
| WO-2005044289-A2 | AN EXTRACT OF THE FRUIT OF SCHISANDRA CHINENSIS AND ITS PHARMACEUTICAL AND COSMETIC USE | COGNIS FRANCE, S.A.S. (FR) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005039610-A1 | A PLANT EXTRACT AND ITS PHARMACEUTICAL AND COSMETIC USE | COGNIS FRANCE, S.A.S. (FR) | 2005-05-06 | — | — | WO | disclosed |
| US-20040047832-A1 | Cosmetic and/or dermopharmaceutical preparations containing leaf extracts of the plant argania spinosa | COGNIS FRANCE S.A. (FR) | 2004-03-11 | — | — | US | disclosed |
| US-20040042996-A1 | Cosmetic and/or dermopharmaceutical preparations containing native proteins from the plant argania spinosa | COGNIS FRANCE S.A.S. (FR) | 2004-03-04 | — | — | US | disclosed |
| US-20030175366-A1 | Plant Extracts and Methods of Treating Skin Therewith | COGNIS FRANCE, S.A. (FR) | 2003-09-18 | — | — | US | disclosed |
| US-20030138394-A1 | Cosmetic and/or pharmaceutical preparations that contain an extract of the plant argania spinosa | COGNIS FRANCE S.A. (FR) | 2003-07-24 | — | — | US | disclosed |
| US-20030068364-A1 | Pro-liposomal encapsulated preparations (iv) | COGNIS IBERIA S.L (ES) | 2003-04-10 | — | — | US | disclosed |
| US-20030003070-A1 | Use of nanoscale active anti-dandruff ingredients | COGNIS DEUTSCHLAND GMBH & CO. KG (DE) | 2003-01-02 | — | — | US | disclosed |
| US-4355021-A | Virucidal wipe and method | S. C. JOHNSON & SON, INC. (US) | 1982-10-19 | — | — | US | disclosed |
| US-4307089-A | ANTIDANDRUFF, FUNGICIDES BACTERICIDES | REWO CHEMISCHE WERKE GMBH (DE) | 1981-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578110-B2 | Compounds for inducing tissue formation and uses thereof | HDGF, HGF, BMP4 | ALDH1A1 4070/4885LMNA 4104/4885MAPT 4389/4885 |
| US-20030138394-A1 | Cosmetic and/or pharmaceutical preparations that contain an extract of the plant argania spinosa | ARG1, ARG2, CUTA | ALDH1A1 3916/4885LMNA 1498/4885MAPT 1603/4885 |
| US-20240000746-A1 | New Cooling Agents and Preparations Containing Them | TTPA, TREH, TAS2R45 | ALDH1A1 1658/4885LMNA 2062/4885MAPT 1054/4885 |
| US-20230322878-A1 | COMPOUNDS FOR INDUCING TISSUE FORMATION AND USES THEREOF | HDGF, HGF, BMP4 | ALDH1A1 4070/4885LMNA 4104/4885MAPT 4389/4885 |
| US-20030068364-A1 | Pro-liposomal encapsulated preparations (iv) | PHOSPHO1, LIPA, PLIN5 | ALDH1A1 3463/4885LMNA 125/4885MAPT 1456/4885 |
| US-11633407-B2 | Botanical extracts and compounds from Schinus plants and methods of use | BROX, C5, SYMPK | ALDH1A1 1161/4885LMNA 3903/4885MAPT 3463/4885 |
| US-20040047832-A1 | Cosmetic and/or dermopharmaceutical preparations containing leaf extracts of the plant argania spinosa | CUTA, ARG1, ARG2 | ALDH1A1 3323/4885LMNA 199/4885MAPT 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.